12 February – Webinar in connection with year-end report
Alligator hosted a webinar and conference call for investors, analysts where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the 2025 year-end report. The presentation was followed by a Q&A session.
The recording can be requested via >> this link <<.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Invitation to Alligator Bioscience’s earnings call on 5 May 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno …
Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026
Lund, Sweden – 23 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Shanghai Henlius Biotech, Inc …
New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026
Lund, Sweden – 20 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing …